We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
DefiniGEN strengthens Board with the appointment of Professor Sir John Savill
News

DefiniGEN strengthens Board with the appointment of Professor Sir John Savill

DefiniGEN strengthens Board with the appointment of Professor Sir John Savill
News

DefiniGEN strengthens Board with the appointment of Professor Sir John Savill

Sir John Savill
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "DefiniGEN strengthens Board with the appointment of Professor Sir John Savill"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

DefiniGEN, the world leader in human iPSC differentiation and disease modeling, announces the appointment of Professor Sir John Savill as a Non-Executive Director of the Board. Sir John will bring his expertise in translational science to DefiniGEN enabling the company to accelerate the development of new products and services which can improve the efficiency and economics of drug development.

Sir John Savill was previously the Chief Executive of the Medical Research Council (MRC) in the UK. Within this role he was responsible to UK Parliament for expenditure of approximately £800 million per year as MRC’s Accounting Officer. Alongside the MRC role, Savill was also Vice-Principal and Head of the College of Medicine at the University of Edinburgh. As a renowned expert in research and innovation, Sir John will aid DefiniGEN in further developing its partnerships with the pharmaceutical and biomedical communities.

Dr Marcus Yeo, Chief Executive Officer, commented: “I am delighted to welcome John to the DefiniGEN board. With his extensive experience as a highly-regarded clinician and scientist I am confident that John will prove to be highly valuable as DefiniGEN continues to grow internationally in key markets.”

Sir John Savill stated: “DefiniGEN is one of the UK’s most innovative translational science companies providing valuable tools for biomedical research. I’m delighted to join the board at this important stage in the company’s development.”
Advertisement